Results 31 to 40 of about 4,520 (170)

A Rare Case of Paxlovid-Induced Pancreatitis

Cureus, 2023
Acute pancreatitis can result secondary to an inflammatory cascade due to an insult to the pancreatic parenchyma, whether it be from infections, medications, etc. We present a case of a 37-year-old male with acute pancreatitis after being started on Paxlovid, a combination drug containing Nirmatrelvir and Ritonavir, for COVID-19 treatment.
Zaidi, Syed Muhammad Hussain, Iskander, Peter A, Ahmed, Khalid, Jaber, Fouad, Paz, Merlin, Khan, Ali, Malik, Fahad, Aloysius, Mark M   +7 more
openaire   +2 more sources

Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant

Frontiers in Pediatrics, 2023
ObjectiveTo summarize the clinical characteristics of children with hematological malignancies co-infected with novel coronavirus and explore the safety and effectiveness of Paxlovid treatment.MethodsFrom December 10, 2022, to January 20, 2023, the ...
Yixian Li, Yong Liu, Luping Wen, Hui Chen, Wenqing Wang, Mengyao Tian, Yucai Cheng, Hongman Xue, Chun Chen   +8 more
doaj   +1 more source

Serotonin Syndrome Precipitated by Paxlovid Initiation

Cureus, 2023
A female in her early 40s taking buspirone, quetiapine, and daily kratom presented to the emergency department two days after starting a course of Paxlovid for a mild COVID-19 infection with diffuse tremors, ocular clonus, diaphoresis, and confusion consistent with serotonin syndrome (SS).
Nasser, Nicholas G, Welsh, Connor, Mitra, Avir, Swan, Matthew   +3 more
openaire   +2 more sources

REBOUND COVID-19 AFTER PAXLOVID IN 2 RELATED FAMILY MEMBERS

International Journal of Infectious Diseases, 2023
Intro: On May 24, 2022, the CDC issued a healthcare advisory after reports of COVID-19 symptoms returning (COVID-19 rebound) in certain patients two to eight days after treatment with Paxlovid (Ritonavir-Boosted Nirmatrevir). We describe two patients who
P. Periyasamy, T. Li Fen, N. Kori, U.A. Zainulabid   +3 more
doaj   +1 more source

Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients

Infectious Diseases and Therapy, 2023
Introduction Elderly patients are the most affected and vulnerable to COVID-19 and effective therapeutic interventions are urgently required. We clarified the safety and efficacy of Paxlovid in the treatment of elderly patients with coronavirus disease ...
Chengzhao Weng, Rongcheng Xie, Guanjie Han, Ya Yuan, Shiqin Li, Chao Wang, Xiaofeng Wang, Wei Jiang, Libo Jiang   +8 more
doaj   +1 more source

Paxlovid™ reduces the incidence of pneumonia, hospitalization, and death in a cohort of COVID-19 patients from northeast Mexico

Journal of Infection and Public Health
Background: Information on Paxlovid™ effectiveness must be monitored and updated in real world scenarios. Our research question was what is the effectiveness of Paxlovid™ in adult patients with COVID-19?
María Elena Camacho Moll, Ana Maria Salinas Martínez, Minna Wu, Gloria Navarrete Floriano, Juan Carlos Romo Salazar, Jorge Eleazar Cruz Luna, Mario Bermúdez de León   +6 more
doaj   +1 more source

A case report of severe hyponatremia secondary to Paxlovid‐induced SIADH

Clinical Case Reports, 2023
Key Clinical Message Nirmatrelvir‐ritonavir (Paxlovid) is a brand‐new oral antiviral medication for treating mild to severe COVID‐19. The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for ritonavir‐nirmatrelvir on ...
Sarah Mohamed, Mostafa Reda Mostafa, Mohamed Magdi Eid, Yossef Hassan AbdelQadir, Yomna Ali Abdelghafar, Sarya Swed, Bishara Jahshan, Waddah Abd El‐Radi   +7 more
doaj   +1 more source

RECOVER Query: Paxlovid

, 2022
The overall goals of this query are to 1) characterize the growth in patients receiving Paxlovid over time and 2) examine Paxlovid use by patient characteristics, including by acute SARS CoV-2 infection profile and healthcare utilization. Patients with a COVID index date or a visit date between 12/1/2021 (7 days before EUA) and 5/30/2022 are included ...
openaire   +1 more source

Survival benefit and safety evaluation of probiotic supplementation in omicron‐infected patients: Real‐world evidence from a multicenter 12,615‐patient cohort

VIEW, EarlyView.
Probiotic supplements have shown benefits in reducing all‐cause mortality among hospitalized patients with SARS‐CoV‐2 infection. Patients with severe illness or without antiviral treatment were more likely to use probiotic supplements. Probiotic supplements may be a promising adjunctive therapy for SARS‐CoV‐2 infection.
Mengzhao Yang, Shanshuo Liu, Junyi Sun, Fuwei Wang, Guangyun Zhu, Xinjun Hu, Guowu Qian, Yiqiang Yuan, Hong Luo, Shixi Zhang, Guangming Li, Donghua Zhang, Guotao Li, Zujiang Yu, Zhigang Ren   +14 more
wiley   +1 more source

Paxlovid: Mechanism of Action, Synthesis, and In Silico Study

BioMed Research International, 2022
In this work, the discovery and description of PF‐07321332, a major bioavailable oral SARS‐CoV‐2 protease inhibitor with in vitro human coronavirus antiviral activity, and excellent selection of off‐target and in vivo immune profiles are reported. Various drugs and novel compound candidates for the treatment of the COVID‐19 pandemic have been developed.
Mahrokh Marzi, Mohammad Kazem Vakil, Maryam Bahmanyar, Elham Zarenezhad   +3 more
openaire   +2 more sources